FDA's broad plan for dealing with opioid medicines could eliminate at least one roadblock to Robert Califf's confirmation as FDA commissioner.
On Feb. 4, Califf, currently FDA deputy commissioner for medical products and tobacco, and other agency officials announced a plan "to reassess the agency's approach to opioid medications
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?